Olin Business School

After two yeas of pivot and patience, three reunion classes — the Classes of ’70, ’71 and ’72 — got together to celebrate 50th reunions at this year’s Commencement.

After a distinguished career in international banking and hospitality investing, Albert Ip, BSAMCS ’73, advocates for WashU in Hong Kong.

As founder and CEO of City Winery, a national chain of music venues that offers wine and fine dining, Michael Dorf, AB ’84, BSBA ’84, has made it his mission to provide an experience that will “indulge the senses.”

As the new adviser at the Washington University Office of Military & Veteran Services, Beverly Wagner is eager to help Washington University’s veterans, active-duty and Reserve and National Guard service members, as well as dependents and survivors, maximize their WashU experience.

If changes at Twitter conflict with businesses’ values, it’s time for companies to re-evaluate use of the social media platform, said Olin Business School marketing expert Michael Wall.

Voters in this year’s midterm elections, to be held nationwide Nov. 8, will be motivated by a number of hot-button issues, including abortion, climate change, voting rights, the economy and more. Washington University faculty experts weigh in on some of the issues that will be top of voters’ minds as they head to the polls.

Nicole Briceño, a first-year student at Washington University, took part in the National LOFT Leadership Institute Open Space Summit and the 35th Hispanic Heritage Month Celebration in September in Washington.

Philip H. Dybvig, a banking and finance expert at Washington University in St. Louis, is one of three economists to share the 2022 Nobel Prize in economic sciences, the Royal Swedish Academy of Sciences announced Monday, Oct. 10.

New Olin Business School research suggests those touched by the sometimes devastating effects of the COVID-19 pandemic are now more likely to recognize sources of inequality and, in turn, advocate for greater equality in the United States.

The White House has sounded the alarm about vulnerabilities in the pharmaceutical supply chain. But new research from the Center for Analytics and Business Insights at Olin Business School found that the U.S. actually has the capacity to make the nation’s most essential and critical drugs — yet it’s mostly sitting idle.